ISIN: FR0010907956 | Ticker: ALCAR | LEI: 969500ARXACM0P0KH333
Sector: Health CareSub-Industry: Health Care Equipment
Country: France


Company Description

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts.

The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States.

Year founded


Served area



Immeuble l'Etendard 36 Avenue de l'Europe, 78141 Vélizy-Villacoublay Cedex – France

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.01.24 None Other Other EUR 1,499,996.61
29.01.24 None Other Other EUR 249,997.44
23.10.23 None Other Other EUR 6,999,991.20
23.10.23 None Other Other EUR 3,749,997.60
23.10.23 None Other Other EUR 499,996.80
19.10.23 None Other Sell EUR 33,200.00
15.10.23 None Other Other EUR 3,749,997.60

Capital markets information






Health Care

Industry Group

Health Care Equipment & Services


Health Care Equipment & Supplies


Health Care Equipment

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.